-32%

est. 2Y upside i

HealthcareSeries B

Rank

#2978

Sector

Healthcare IT

Est. Liquidity

~2Y

Data Quality

Data: Low

Given the stale valuation mark and severe preference overhang, expected upside is -31.6%.

Last updated: July 19, 2026

Bull (20%)+60%

With 20% probability, an IPO window opens and AKASA achieves category leadership, supporting a 10x forward revenue multiple. At $72.1M projected revenue, exit value of ~$721M yields 60% upside despite preference overhang.

Base (35%)+4%

With 35% probability, multiple converges to public comp range of 6.5x, yielding exit value ~$469M and modest 4% upside, barely exceeding preference hurdle.

Bear (45%)-100%

With 45% probability, multiple compresses to 3x and exit value of $216M falls below $258M total funding, leaving common stock worthless (-100% return).

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

5730%

Total funding of $258M represents 57% of estimated entry valuation, creating a severe overhang that subordinates common stock.

Dilution Risk

low

Given $258M total funding and $120M recent round, dilution from future financings is unlikely within 2 years.

Secondary Liquidity

none

No secondary market activity detected; likely illiquid.

Deployment Customer Engagement 2 roles

General & Administration 1 role

Marketing 1 role

Product 1 role

Sales & Customer Success 1 role

View all 15 open roles at Akasa

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Akasa's data — designed to show you've done your homework.

  • 1

    How does AKASA's AI defend against EHR-led native automation?

  • 2

    What is the unit economics of a typical hospital contract and how do they scale?

  • 3

    Given the preference stack, what is the realistic range of common stock value under various exit scenarios?

Community

Valuation Sentiment

Our model estimates -32% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.